Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2026-04-06
DOI
https://doi.org/10.1073/pnas.2518347123
Citations
1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
13.60

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Inga Rose, Xiaohui Ni, W. Li, Xianghong Jasmine Zhou et al.
1 citations
Proceedings of the National Academy of Sciences
Cancer Genomics and Diagnostics
13.60
article

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Inga Rose, Xiaohui Ni, W. Li, Xianghong Jasmine Zhou, S. Guo-Dong Li, Y. Zhou, Caitlin Tang, David S. Lu, Weihua Zeng, David Yuanze Li, Xiyan Xiang
article en
1 citations

Abstract

achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.

Proceedings of the National Academy of SciencesVol. 123(15)
QB3 (US), University of Southern California (US), University of Maryland, Baltimore (US), Feinstein Institute for Medical Research (US), University of California, Los Angeles (US), George Washington University (US), University of California System (US), Quantitative BioSciences (US), Credo Reference (United States) (US), Center for Digestive and Liver Diseases (US), Laboratoire National de Référence (MA), Precision for Medicine (United States) (US), USC Norris Comprehensive Cancer Center (US), Samueli Institute (US), Crown Bioscience (China) (CN), Broad Center (US), VA Greater Los Angeles Healthcare System (US), VPDiagnostics (United States) (US), Sage (United Kingdom) (GB), Stanford University (US)
National Science Foundation, American Association for Cancer Research, LUNGevity Foundation, Tobacco-Related Disease Research Program, UCLA Health System, National Institutes of Health, Stand Up To Cancer, National Heart, Lung, and Blood Institute, National Institute of Mental Health, National Human Genome Research Institute, NIH Office of the Director, National Cancer Institute, David Geffen School of Medicine, University of California, Los Angeles, Common Fund, National Science Foundation Graduate Research Fellowship Program
Good health and well-being
Openalex Percentile: Top 1%
Cancer Genomics and Diagnostics
13.60
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.